What's new? Log in Free sign up

AstraZeneca (AZN)

Company Profile

Company profile

Ticker

AZN, AZNCF

Exchange

Website

www.astrazeneca.com

CEO

Mr. Pascal Soriot D.V.M., M.B.A.

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

ZENECA GROUP PLC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

AZN stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Tagrisso Approved In Eu Based on Laura Trial

Directorate Change

Imfinzi Approved In Us for Limited-stage SCLC

Astrazeneca Appoints Iskra Reic Evp International

Truqap Improved RPFS In Advanced Prostate Cancer

Director/pdmr Shareholding

Tagrisso Recommended for Eu Approval - Laura

Director/pdmr Shareholding

Director/pdmr Shareholding

Director/pdmr Shareholding

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Monopar Therapeutics

CONDUIT PHARMACEUTICALS INC.

Annual report of employee stock purchases

ADC Therapeutics SA

Notice of proposed sale of securities

Annual report of employee stock purchases

Aridis Pharmaceuticals, Inc.

Financial summary

Financial statements Chart AZN financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from AstraZeneca earnings reports.

Institutional ownership, Q2 2023

AZN institutional ownership history Ownership history

0.0% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	3	4	-25.0%
Opened positions	0	1	EXIT
Closed positions	1	1	–
Increased positions	1	0	NEW
Reduced positions	0	1	EXIT

13F shares	Current	Prev Q	Change
Total value	45.00 mm	37.80 mm	+19.1%
Total shares	313.89 k	272.14 k	+15.3%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Boston Common Asset Management	313.07 k	$44.88 mm	+15.5%
Vigilant Capital Management	647.00	$93.00 k	0.0%
Strengthening Families & Communities	178.00	$26.00 k	0.0%

Largest transactions	Shares	Bought/sold	Change
Boston Common Asset Management	313.07 k	+41.94 k	+15.5%
Byrne Asset Management	0.00	-186.00	EXIT
Vigilant Capital Management	647.00	0.00	0.0%
Strengthening Families & Communities	178.00	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer

The FDA delays Johnson & Johnson's SC amivantamab approval for NSCLC over facility inspection issues, unrelated to product safety or efficacy

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.

"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News

https://www.bloomberg.com/news/articles/2024-12-13/ozempic-craze-appears-to-be-curbing-us-obesity-epidemic

United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis

AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients

Press releases

From Benzinga Pro

AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses; February 21, 2025 Deadline to file Lead Plaintiff Motion

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises AstraZeneca PLC ("AstraZeneca PLC" or the

AZN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead the AstraZeneca Class Action Lawsuit

SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ:AZN) publicly traded securities between February 23, 2022 and December

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of AstraZeneca PLC Investors – AZN

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of AstraZeneca PLC (NASDAQ:AZN) between February 23, 2022 and December 17, 2024,

AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman

AstraZeneca PLC Announcement: If You Have Suffered Losses in AstraZeneca PLC (NASDAQ: AZN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.